ω-3 carboxylic acids for hypertriglyceridemia

Bibliography

• Christian JB, Bourgeois N, Snipes R, et al. Prevalence of severe (500 to 2,000 mg/dL) hypertriglyceridemia in United States adults. Am J Cardiol 2011;107:891-7
   PubMed Web of Science ®Google Scholar
• National Cholesterol Education Panel. Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation 2002;106:3143-421
   PubMed Web of Science ®Google Scholar
• Chapman MJ, Ginsberg HN, Amarenco P, et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J 2011;32:1345-61
   PubMed Web of Science ®Google Scholar
• Sarwar N, Sandhu MS, Ricketts SL, et al. Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet 2010;375:1634-9
   PubMed Web of Science ®Google Scholar
• Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013;ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;63(25 Pt B):2889-934
   Google Scholar
• Miller M, Stone NJ, Ballantyne C, et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 2011;123:2292-333
   PubMed Web of Science ®Google Scholar
• Wang L, Gill R, Pedersen TL, et al. Triglyceride-rich lipoprotein lipolysis releases neutral and oxidized FFAs that induce endothelial cell inflammation. J Lipid Res 2009;50:204-13
   PubMed Web of Science ®Google Scholar
• Werner C, Filmer A, Fritsch M, et al. Risk prediction with triglycerides in patients with stable coronary disease on statin treatment. Clin Res Cardiol 2014;103(12):984-97
   Google Scholar
• Loss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease. The TG and HDL working group of the exome sequencing project, national heart, lung, and blood institute. N Engl J Med 2014;371:22-31
   Google Scholar
• Jorgensen AB, Frikke-Schmidt R, Nordestgaard BG, et al. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med 2014;37(1):32-41
   Google Scholar
• Goldberg IJ, Eckel RH, McPherson R. Triglycerides and heart disease: still a hypothesis? Arterioscler Thromb Vasc Biol 2011;31:1716-25
   PubMed Web of Science ®Google Scholar
• Nordestgaard BG, Varbo A; Lipids and cardiovascular disease 3. Triglycerides and cardiovascular disease. Lancet 2014;384:626-35
   PubMed Web of Science ®Google Scholar
• Hegele RA, Ginsberg HN, Chapman MJ. The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol 2014;2(8):655-66
   PubMed Web of Science ®Google Scholar
• Kromhout D, de Goede J. Update on cardiometabolic health effects of ω-3 fatty acids. Curr Opin Lipidol 2014;25:85-90
   PubMed Web of Science ®Google Scholar
• Ford ES, Li C, Zhao G, et al. Hypertriglyceridemia and its pharmacologic treatment among US adults. Arch Intern Med 2009;169:572-8
   PubMedGoogle Scholar
• Center for Disease Control, Incidence of childhood obesity. Available from: www.cdc.gov/healthyyouth/obesity/facts.htm [Accessed 24 Aug 2014]
   Google Scholar
• Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. The AIM-HIGH Investigators. N Engl J Med 2011;365:2255-67
   PubMed Web of Science ®Google Scholar
• Effects of extended-release niacin with laropiprant in high-risk patients: the HPS2-THRIVE collaborative group. N Engl J Med 2014;371:203-12
   PubMed Web of Science ®Google Scholar
• Prueksaritanont T, Zhao JJ, Ma B, et al. Mechanistic studies on metabolic interactions between gemfibrozil and statins. J Pharmacol Exp Ther 2002;301(3):1042-51
   Google Scholar
• Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus. The ACCORD Study Group N Engl J Med 2010;362:1563-74
   Google Scholar
• Available from: https://www.gsksource.com/gskprm/htdocs/documents/LOVAZA-PI-PIL.PDF Accessed 15 September 2014]
   Google Scholar
• Available from: http://www.vascepa.com/full-prescribing-information.pdf Accessed 15 September 2014]
   Google Scholar
• Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204977s000lbl.pdf [Accessed 15 September 2014]
   Google Scholar
• Available from: http://www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/drugandbiologicapprovalreports/andagenericdrugapprovals/ucm397396.htm [Accessed 15 September 2014]
   Google Scholar
• Hui DY, Howles PN. Carboxyl ester lipase: structure-function relationship and physiological role in lipoprotein metabolism and atherosclerosis. J Lipid Res 2002;43(12):2017-13
   PubMed Web of Science ®Google Scholar
• Available from: http://www1.astrazeneca-us.com/pi/epanova.pdf [Accessed 14 September 2014]
   Google Scholar
• Davidson MH, Johnson J, Rooney MW, et al. A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: the ECLIPSE (Epanova compared to Lovaza in a pharmacokinetic single-dose evaluation) study. J Clin Lipidol 2012;6:573-84
   PubMed Web of Science ®Google Scholar
• Harris WS, Bulchandani D. Why do omega-3 fatty acids lower serum triglycerides? Curr Opin Lipidol 2006;17(4):387-93
   PubMed Web of Science ®Google Scholar
• Kastelein JJ, Maki KC, Susekov A, et al. Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the Epanova for Lowering Very high triglycerides (EVOLVE) trial. J Clin Lipidol 2014;8(1):94-106
   PubMed Web of Science ®Google Scholar
• Sahebkar A, Chew GT, Watts GF. Recent advances in pharmacotherapy for hypertriglyceridemia. Prog Lipid Res 2014;56:47-66
   PubMed Web of Science ®Google Scholar
• Chan DC, Barrett PHR, Watts GF. The metabolic and pharmacologic bases for treating atherogenic dyslipidaemia. Best Pract Res Cl En 2014;28:369-85
   Google Scholar
• Feagan BG, Sandborn WJ, Mittmann U, et al. Omega-3 free fatty acids for the maintenance of remission in Crohn disease: the EPIC Randomized Controlled Trials. JAMA 2008;299(14):1690-7
   PubMed Web of Science ®Google Scholar
• Offman E, Marenco T, Ferber S, et al. Steady-state bioavailability of prescription omega-3 on a low-fat diet is significantly improved with a free fatty acid formulation compared with an ethyl ester formulation: the ECLIPSE II study. Vasc Health Risk Manag 2013;9:563-73
   PubMedGoogle Scholar
• Maki KC, Orloff DG, Nicholls SJ, et al. A highly bio available omega 3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT Trial). Clin Ther 2013;35(9):1400-11
   PubMed Web of Science ®Google Scholar
• Available from: http://clinicaltrials.gov/show/NCT02104817 [Accessed 14 September 2014]
   Google Scholar
• Available from: http://clinicaltrials.gov/show/NCT01492361 Accessed 14 September 2014]
   Google Scholar
• EFSA Panel on Dietetic Products, Nutrition and Allergies. NDA Scientific Opinion on the Tolerable Upper Intake Level of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and docosapentaenoic acid (DPA). EFSA Journal 2012;10(7):2815
   Google Scholar